

Breast Cancer Recurrence in the Chest Wall Successfully Treated with TS-1

Maya FUKUYO, Yasuteru YOSHINAGA, Yasuko HAGIO and Akinori IWASAKI

Department of Thoracic, Breast endocrine and Pediatric Surgery,
Faculty of Medicine, Fukuoka University

Abstract : Both clinical efficacy and the quality of life (QOL) should be taken into consideration when treating elderly patients with recurrent breast cancer. The oral combined fluoropyrimidine, TS-1 (tegafur, gimeracil, and oteracil), is a novel anticancer drug. The patient was a 74-year-old female with a recurrence of invasive breast cancer in the wall of her left chest. She had undergone a radical mastectomy 27 years previously to treat left breast cancer. We diagnosed the recurrence as a triple-negative cancer by core needle biopsy and treated her with 4 courses of oral TS-1 alone, and the tumor clinically disappeared. The only adverse event observed during TS-1 therapy was Grade 2 general fatigue, but there was no decline in the patient's QOL. We therefore consider TS-1 to be a feasible antitumor agent for metastatic or recurrent breast cancer that can prevent a decrease in the QOL, thus making it especially suitable for elderly patients.

Key words : Breast cancer, Recurrence, TS-1, Chest wall tumor, Elderly patient